AstraZeneca and Ironwood Pharmaceuticals say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints. …read more Source: AstraZeneca, Ironwood score PhIII success in China
Sanofi has re-upped with its partners at Medicines for Malaria Venture in hopes of developing a single-dose treatment for the infectious disease, advancing a pair of candidates through mid-stage development. …read more Source: Sanofi advances a one-shot malaria program as drug resistance spreads
Back in February, Afferent Pharmaceuticals pronounced itself satisfied with the outcome for a mid-stage study of its lead drug, AF-219, being developed for a range of conditions including pain, persistent coughing and urinary urgency. And today the venture backers behind the San Mateo-based biotech have come up with $55 million in a crossover round to […]
Parisian drug developer Gensight Biologics is swinging for a $100 million U.S. IPO to fund its work on potential one-time treatments for serious retinal diseases, angling to take advantage of a bullish market for biotechs. …read more Source: Gensight scouts a $100M IPO for its ocular gene therapies
Partners Merck and Samsung Bioepis cleared late-stage trials with their knockoff of Humira, the world’s top-selling medicine, setting the stage for global regulatory applications as the reference treatment comes off patent. …read more Source: Merck and Samsung’s Humira biosimilar comes through in Phase III
The FDA has approved Novartis’ big 2015 blockbuster, the heart failure drug Entresto, better known in development circles as LCZ696. …read more Source: UPDATED: FDA OKs Novartis’s megablockbuster heart failure drug Entresto
Imperial Innovations is negotiating with pharma companies over its gene therapy that has shown the potential to treat cystic fibrosis. A trial of the gene therapy posted patchy but promising data this week, putting the tech-transfer business in a position to strike a deal for further development. …read more Source: Imperial Innovations shopping cystic fibrosis […]
The World Health Organization has chided one of India’s biggest CROs over mishandling clinical trial results, echoing a data scandal that threatens to tarnish the reputation of the country’s biopharma contractors. …read more Source: Another Indian CRO runs afoul of global authorities over trial errors
Essex Woodlands is making progress with its ninth life sciences fund. The group noted in an SEC filing that it has raised $360 million of a planned $750 million fund, up from the $221 million it had raised and then reported last year. …read more Source: Essex Woodlands raises $360M for new life sciences fund […]
It’s time to start getting ready for the 14th annual Fierce 15. And if you have a biotech you’d like to nominate for the award, we’ve got a quick and easy form for you to fill out. …read more Source: Listen up! It’s time to nominate top biotechs for the Fierce 15
